EUVIMEDEUVIMED entdecken
Crossref

Components of metabolic syndrome affect COVID-19 outcomes via platelet aggregation

Qian Yu, Masako Nishikawa, Yuqi Zhou, Hongqian Zhang, Huidong Wang, Junyu Chen, Takeya Tsutsumi, Makoto Kurano, Yutaka Yatomi, Shenghong Ju, Keisuke Goda

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.01.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Qian Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The University of Tokyo, Tokyo, Japan; Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventio…. Hauptthemen laut MEDLINE: Metabolic Syndrome, COVID-19, Platelet Aggregation, Blood Platelets. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Konica Minolta Science and Technology Foundation, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Emerging evidence suggests that platelet activation and aggregation are common factors in both metabolic syndrome (MetS) and severe COVID-19, emphasizing the need to investigate their biological connection. OBJECTIVES: We hypothesized that enhanced platelet aggregation mediates the association between MetS and severe COVID-19. This study aimed to determine whether platelet aggregation serves as a mechanistic link between MetS and COVID-19 severity and to develop an image-based biomarker capable of predicting severe disease. METHODS: We conducted massive image-based profiling of circulating platelets in a retrospective cohort of 327 COVID-19 patients (63.9% male; median age, 59.0 years) with metabolic records. Morphologic features of platelets, including shape, density and radial distribution, and texture, were extracted. A machine learning model was developed to construct the COVID-19 Platelet Aggregate Formation Index (CoPAFI), which could quantitatively reflect platelet aggregation and predict severe COVID-19. Mediation analysis was then performed to quantify the extent to which platelet aggregation mediated the association between components of MetS and severe COVID-19. RESULTS: The CoPAFI predicted severe COVID-19 with an area under the curve of 0.82 and an odds ratio of 3.76 (95% CI, 2.63-5.38). The CoPAFI was strongly associated with a hypercoagulable state and served as a reliable indicator for assessing the risk of severe COVID-19. In patients with components of MetS, platelet aggregation, as measured by the CoPAFI, accounted for approximately 25% of the increased severity of COVID-19. CONCLUSION: Enhanced platelet aggregation partially mediates the impact of components of MetS on COVID-19 severity, accounting for approximately 25% of the association, emphasizing the need for integrated metabolic and coagulation management in COVID-19 treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeCOVID-19Platelet AggregationBlood PlateletsHumansRetrospective StudiesMiddle AgedSARS-CoV-2FemaleMaleSeverity of Illness IndexAgedBiomarkersRisk FactorsMachine LearningPredictive Value of Tests

Stichwörter der Autor:innen

COVID-19biomarkerimage-based profilingmediation analysismetabolic syndrome

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Chemistry, The University of Tokyo, Tokyo, Japan; Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda…
  • Deaprtment of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
  • Department of Chemistry, The University of Tokyo, Tokyo, Japan. Electronic address: yuqi@g.ecc.u-tokyo.ac.jp.
  • Department of Chemistry, The University of Tokyo, Tokyo, Japan.
  • Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan; Department of Infection Prevention and Control, The University of Tokyo Hospital, Tokyo, Japan.
  • Deaprtment of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan; Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan.

Förderung

  • Konica Minolta Science and Technology Foundation
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Southeast University
  • Ogasawara Foundation
  • Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering
  • Ogasawara Foundation for the Promotion of Science and Engineering

Zitieren

APA

Yu, Q., Nishikawa, M., Zhou, Y., Zhang, H., Wang, H., Chen, J., Tsutsumi, T., Kurano, M., Yatomi, Y., Ju, S., & Goda, K. (2026). Components of metabolic syndrome affect COVID-19 outcomes via platelet aggregation. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.01.002

Vancouver

Yu Q, Nishikawa M, Zhou Y, Zhang H, Wang H, Chen J, et al. Components of metabolic syndrome affect COVID-19 outcomes via platelet aggregation. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.01.002

BibTeX
@article{Yu2026,
  author = {Yu, Qian and Nishikawa, Masako and Zhou, Yuqi and Zhang, Hongqian and Wang, Huidong and Chen, Junyu and Tsutsumi, Takeya and Kurano, Makoto and Yatomi, Yutaka and Ju, Shenghong and Goda, Keisuke},
  title = {Components of metabolic syndrome affect COVID-19 outcomes via platelet aggregation},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.01.002}
}
Kostenlos starten →